Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial

NCT ID: NCT07022704

Last Updated: 2025-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-22

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Mechanical Ventilation Weaning From Mechanical Ventilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doxapram

All patients will receive doxapram during spontaneous breathing trial

Doxapram

Intervention Type DRUG

Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxapram

Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial

Exclusion Criteria

* Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mina Adolf Helmy

Lecturer of anesthesia and critical care

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo University

Cairo, Cairo Governorate, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mina Helmy, MD

Role: CONTACT

+201007174836

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cairo University

Role: primary

01007174836

References

Explore related publications, articles, or registry entries linked to this study.

Helmy MA, Magdy Milad L, Osman SH, Ali MA, Hasanin A. Diaphragmatic excursion: A possible key player for predicting successful weaning in patients with severe COVID-19. Anaesth Crit Care Pain Med. 2021 Jun;40(3):100875. doi: 10.1016/j.accpm.2021.100875. Epub 2021 Apr 30. No abstract available.

Reference Type BACKGROUND
PMID: 33940248 (View on PubMed)

Pourriat JL, Baud M, Lamberto C, Fosse JP, Cupa M. Effects of doxapram on hypercapnic response during weaning from mechanical ventilation in COPD patients. Chest. 1992 Jun;101(6):1639-43. doi: 10.1378/chest.101.6.1639.

Reference Type BACKGROUND
PMID: 1600786 (View on PubMed)

Oikawa S, Nomura H, Nishio M, Nagata R, Hata T. Doxapram hydrochloride aggravates adrenaline-induced arrhythmias accompanied by bidirectional ventricular tachycardia. ISRN Cardiol. 2014 Jan 9;2014:212045. doi: 10.1155/2014/212045. eCollection 2014.

Reference Type BACKGROUND
PMID: 24527224 (View on PubMed)

Rutka M, Palac M, Linek P. Diaphragmatic Mobility Loss in Subjects With Moderate to Very Severe COPD May Improve After In-Patient Pulmonary Rehabilitation. Respir Care. 2021 Feb;66(2):354. doi: 10.4187/respcare.08687. No abstract available.

Reference Type BACKGROUND
PMID: 33514664 (View on PubMed)

Scheibe N, Sosnowski N, Pinkhasik A, Vonderbank S, Bastian A. Sonographic evaluation of diaphragmatic dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015 Sep 11;10:1925-30. doi: 10.2147/COPD.S85659. eCollection 2015.

Reference Type BACKGROUND
PMID: 26392767 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Doxapram in COPD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.